IL285184B2 - Sulcardine salts - Google Patents

Sulcardine salts

Info

Publication number
IL285184B2
IL285184B2 IL285184A IL28518421A IL285184B2 IL 285184 B2 IL285184 B2 IL 285184B2 IL 285184 A IL285184 A IL 285184A IL 28518421 A IL28518421 A IL 28518421A IL 285184 B2 IL285184 B2 IL 285184B2
Authority
IL
Israel
Prior art keywords
sulcardine
salt
crystalline
peaks
acid
Prior art date
Application number
IL285184A
Other languages
English (en)
Hebrew (he)
Other versions
IL285184A (en
IL285184B1 (en
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of IL285184A publication Critical patent/IL285184A/en
Publication of IL285184B1 publication Critical patent/IL285184B1/en
Publication of IL285184B2 publication Critical patent/IL285184B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
IL285184A 2019-01-29 2020-01-28 Sulcardine salts IL285184B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798467P 2019-01-29 2019-01-29
US202062959687P 2020-01-10 2020-01-10
PCT/US2020/015370 WO2020159959A1 (en) 2019-01-29 2020-01-28 Sulcardine salts

Publications (3)

Publication Number Publication Date
IL285184A IL285184A (en) 2021-09-30
IL285184B1 IL285184B1 (en) 2023-08-01
IL285184B2 true IL285184B2 (en) 2023-12-01

Family

ID=69724142

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285184A IL285184B2 (en) 2019-01-29 2020-01-28 Sulcardine salts

Country Status (16)

Country Link
US (3) US11426382B2 (https=)
EP (1) EP3917921A1 (https=)
JP (3) JP2022518906A (https=)
KR (2) KR102405199B1 (https=)
CN (2) CN115385871A (https=)
AU (1) AU2020216925B2 (https=)
BR (1) BR112021014640A8 (https=)
CA (1) CA3128152A1 (https=)
CL (1) CL2021001968A1 (https=)
CO (1) CO2021011042A2 (https=)
IL (1) IL285184B2 (https=)
MX (2) MX2021009033A (https=)
PH (1) PH12021551818A1 (https=)
SG (1) SG11202108160YA (https=)
WO (1) WO2020159959A1 (https=)
ZA (2) ZA202105344B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364223B2 (en) 2018-12-13 2022-06-21 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
CN115385871A (zh) * 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐
CA3182015A1 (en) 2020-06-12 2021-12-16 Gary Elliott Sulcardine administration for treatment of acute atrial fibrillation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062906A2 (en) * 2009-11-17 2011-05-26 Elliot Gary T Treatment of atrial fibrillation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1299813C (zh) 2004-12-28 2007-02-14 华南理工大学 自动撕膜落料及多样性搅拌的机构和控制装置
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
EP2501380B1 (en) * 2009-11-17 2016-01-27 Huya Bioscience International LLC Slow infusion of sulcardine and its salts
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CA3254279A1 (en) 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
CA3023278C (en) 2016-05-05 2019-04-30 Triastek, Inc. Controlled release dosage form
KR20190107712A (ko) 2017-01-26 2019-09-20 트리아스텍 인코포레이티드 특정 위장 부위에서의 제어 방출의 투여 형태
CA3054403A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
US11364223B2 (en) 2018-12-13 2022-06-21 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
CN115385871A (zh) 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062906A2 (en) * 2009-11-17 2011-05-26 Elliot Gary T Treatment of atrial fibrillation

Also Published As

Publication number Publication date
BR112021014640A8 (pt) 2022-12-20
US20200316024A1 (en) 2020-10-08
PH12021551818A1 (en) 2022-03-28
KR102405199B1 (ko) 2022-06-02
AU2020216925B2 (en) 2022-09-15
ZA202105344B (en) 2023-01-25
KR20220079688A (ko) 2022-06-13
KR102697726B1 (ko) 2024-08-21
AU2020216925A1 (en) 2021-09-02
IL285184A (en) 2021-09-30
BR112021014640A2 (pt) 2021-09-21
US20250144072A9 (en) 2025-05-08
US11426382B2 (en) 2022-08-30
CL2021001968A1 (es) 2022-01-28
ZA202107474B (en) 2022-06-29
JP2024039020A (ja) 2024-03-21
IL285184B1 (en) 2023-08-01
EP3917921A1 (en) 2021-12-08
US20210038568A1 (en) 2021-02-11
US11020374B2 (en) 2021-06-01
KR20210130157A (ko) 2021-10-29
JP2022518906A (ja) 2022-03-17
US20220356319A1 (en) 2022-11-10
CO2021011042A2 (es) 2022-01-17
MX2023014776A (es) 2024-01-15
JP2025165933A (ja) 2025-11-05
CN115385871A (zh) 2022-11-25
WO2020159959A1 (en) 2020-08-06
CN112638903B (zh) 2022-08-26
CA3128152A1 (en) 2020-08-06
CN112638903A (zh) 2021-04-09
MX2021009033A (es) 2021-10-13
SG11202108160YA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
IL302651A (en) Integrin inhibitors and their uses
IL259493A (en) Solid dispersions containing sgc actuator
IL285184B2 (en) Sulcardine salts
IL305435A (en) Psilocybin compositions, methods of making and methods of using the same
IL252182B2 (en) Cancer treatment methods
IL292005A (en) Solid-state crystalline forms of a selective potassium channel modulator
IL279853B1 (en) Polymorphic forms of rad 1901-2hcl
IL298525A (en) Pralsetinib pharmaceutical compositions
IL268092B2 (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
IL225808A (en) Sesquihydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate, process for its preparation and pharmaceutical compositions comprising it for treating diabetes and obesity
IL297652B2 (en) Compositions containing methylphenidate prodrugs, processes for their preparation and use
IL312855A (en) ROCK2 inhibitor nanocrystalline preparation and method for its preparation
IL298984A (en) Indan compounds, their pharmaceutical preparations and their medical applications
IL298872A (en) Dosage forms of eclobrutinib maleate
IL322651A (en) Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
IL275153B1 (en) Fumarate salt of (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof
IL315654A (en) Salts of RXR agonists, their crystalline forms and their use
IL295992A (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
HK40079384A (en) Sulcardine salts
HK40049638A (en) Sulcardine salts
HK40049638B (en) Sulcardine salts
TW202521117A (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
KR20250026776A (ko) 고요산혈증 또는 통풍 치료 또는 예방을 위한 화합물의 고체 결정형
EA043571B1 (ru) Соли сулькардина
JP2022514624A (ja) Ｐａｒ４阻害剤の結晶体